Evidence and rationale for vaccinating children and adolescents against SARS-CoV-2: a comprehensive narrative review

Vaccines remain the most rigorous and cost-effective weapon of the public health care system against infectious diseases. The development of safe and effective vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged as an imperative response to the unprecedented morbidity and mortality of the Coronavirus Disease 2019 (COVID-19) pandemic and the subsequent immense pressure on health care systems, families and global society. Despite the typically mild disease course of SARS-CoV-2 in minors, the associated rare but potentially life-threatening complications, as well as the emergence of new highly transmissible variants, led promptly to the extension of COVID-19 vaccine clinical trials in children and adolescents. To date, various COVID-19 vaccine candidates have been successfully trialed in pediatric populations, followed by their incorporation into corresponding vaccination campaigns in both high- and low-income countries. However, the universal COVID-19 vaccination of children and adolescents remains a matter of debate, along with skepticism about their overall safety and benefits in this age group. In this narrative review, we attempt to summarize the multi-faceted burden of COVID-19 on minors, highlighting the favourable safety/effectiveness profile of COVID-19 vaccines in this age group, elucidating the raised concerns and presenting the current implemented vaccination strategies.

SARS-CoV-2; Viral vaccines; mRNA vaccines; Vaccine development; Vaccination hesitancy; Minors; Communicable diseases; Public health

[1] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. The New England Journal of Medicine. 2020; 382: 727–733.

[2] Shi Y, Wang G, Cai X, Deng J, Zheng L, Zhu H, et al. An overview of COVID-19. Journal of Zhejiang University-SCIENCE B. 2020; 21: 343–360.

[3] Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. ActaBiomedica. 2020; 91: 157–160.

[4] Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus pandemic (COVID-19). 2020. Available at: https://ourworldindata.org/coronavirus (Accessed: 13 February 2022).

[5] Gao Y, Ding M, Dong X, Zhang J, KursatAzkur A, AzkurD, et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021; 76: 428–455.

[6] Mantovani A, Rinaldi E, Zusi C, Beatrice G, Saccomani MD, Dalbeni A. Coronavirus disease 2019 (COVID-19) in children and/or adolescents: a meta-analysis. Pediatric Research. 2021; 89: 733–737.

[7] Ravindra K, Malik VS, Padhi BK, Goel S, Gupta M. Asymptomatic infection and transmission of COVID-19 among clusters: systematic review and meta-analysis. Public Health. 2022; 203: 100–109.

[8] Tezer H, Bedir Demirdağ T. Novel coronavirus disease (COVID-19) in children. Turkish Journal of Medical Sciences. 2020; 50: 592–603.

[9] Tsankov BK, Allaire JM, Irvine MA, Lopez AA, Sauvé LJ, Vallance BA, et al. Severe COVID-19 infection and pediatric comorbidities: a systematic review and meta-analysis. International Journal of Infectious Diseases. 2021; 103: 246–256.

[10] Bhopal SS, Bagaria J, Olabi B, Bhopal R. Children and young people remain at low risk of COVID-19 mortality. The Lancet Child & Adolescent Health. 2021; 5: e12–e13.

[11] Kostopoulou E, Sinopidis X, Gidaris D, Karantaglis N, Cassimos D, Gkentzi D, et al. Parents under siege: the psychological impact of COVID-19 outbreak on children’s caregivers. Swiss Medical Weekly. 2021; 151: w30012.

[12] Meherali S, Punjani N, Louie-Poon S, Rahim KA, Das JK, Salam RA, et al. Mental health of children and adolescents amidst COVID-19 and past pandemics: a rapid systematic review. International Journal of Environmental Research and Public Health. 2021; 18: 3432.

[13] Tang S, Xiang M, Cheung T, Xiang Y. Mental health and its correlates among children and adolescents during COVID-19 school closure: the importance of parent-child discussion. Journal of Affective Disorders. 2021; 279: 353–360.

[14] Buonsenso D, Munblit D, De Rose C, Sinatti D, Ricchiuto A, Carfi A, et al. Preliminary evidence on long COVID in children. Acta Paediatrica. 2021; 110: 2208–2211.

[15] Radia T, Williams N, Agrawal P, Harman K, Weale J, Cook J, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation. Paediatric Respiratory Reviews. 2021; 38: 51–57.

[16] Blasi F, Gramegna A, Sotgiu G, Saderi L, Voza A, Aliberti S, et al. SARS-CoV-2 vaccines: a critical perspective through efficacy data and barriers to herd immunity. Respiratory Medicine. 2021; 180: 106355.

[17] Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet. 2021; 397: 1819–1829.

[18] Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines. 2021; 9: 1–15.

[19] Brüssow H. COVID-19 and children: medical impact and collateral damage. Microbial Biotechnology. 2022; 15: 1035–1049.

[20] Zambrano LD, Newhams MM, Olson SM, Halasa NB, Price AM, Boom JA, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12–18 years—United States, July–December 2021. Morbidity and Mortality Weekly Report. 2022; 71: 52–58.

[21] Borrelli M, Corcione A, Castellano F, Fiori Nastro F, Santamaria F. Coronavirus disease 2019 in children. Frontiers in Pediatrics. 2021; 9: 668484.

[22] Nikolopoulou GB, Maltezou HC. COVID-19 in children: where do we stand? Archives of Medical Research. 2022; 53: 1–8.

[23] Cui X, Zhao Z, Zhang T, Guo W, Guo W, Zheng J, et al. A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19). Journal of Medical Virology. 2021; 93: 1057–1069.

[24] Puoti MG, Rybak A, Kiparissi F, Gaynor E, Borrelli O. SARS-CoV-2 and the gastrointestinal tract in children. Frontiers in Pediatrics. 2021; 9: 617980.

[25] Parisi GF, Indolfi C, Decimo F, Leonardi S, Miraglia del Giudice M. COVID-19 pneumonia in children: from etiology to management. Frontiers in Pediatrics. 2020; 8: 891.

[26] Derespina KR, Kaushik S, Plichta A, Conway EE, Bercow A, Choi J, et al. Clinical manifestations and outcomes of critically ill children and adolescents with coronavirus disease 2019 in New York city. The Journal of Pediatrics. 2020; 226: 55–63.e2.

[27] Jahangir M, Nawaz M, Nanjiani D, Siddiqui MS. Clinical manifestations and outcomes of COVID-19 in the paediatric population: a systematic review. Hong Kong Medical Journal. 2021; 27: 35–45.

[28] Wang J, Mo Y, Su Y, Wang L, Liu G, Li M, et al. Computed tomography features of COVID-19 in children. Medicine. 2021; 100: e22571.

[29] Kumar J, Meena J, Yadav A, Yadav J. Radiological findings of COVID-19 in children: a systematic review and meta-analysis. Journal of Tropical Pediatrics. 2021; 67: fmaa045.

[30] Ebrahimpour L, Marashi M, Zamanian H, Abedi M. Computed tomogra-phy findings in 3,557 COVID-19 infected children: a systematic review. Quantitative Imaging in Medicine and Surgery. 2021; 11: 4644–4660.

[31] Akobeng AK, Grafton-Clarke C, Abdelgadir I, Twum-Barimah E, Gordon M. Gastrointestinal manifestations of COVID-19 in children: a systematic review and meta-analysis. Frontline Gastroenterology. 2021; 12: 332–337.

[32] Chiappini E, Licari A, Motisi MA, Manti S, Marseglia GL, Galli L, et al. Gastrointestinal involvement in children with SARS-COV-2 infection: an overview for the pediatrician. Pediatric Allergy and Immunology. 2020; 31: 92–95.

[33] Smyk W, Janik MK, Portincasa P, Milkiewicz P, Lammert F, Krawczyk M. COVID-19: focus on the lungs but do not forget the gastrointestinal tract. European Journal of Clinical Investigation. 2020; 50: e13276.

[34] Pousa PA, Mendonça TSC, Oliveira EA, Simões-e-Silva AC. Extra-pulmonary manifestations of COVID-19 in children: a comprehensive review and pathophysiological considerations. Jornal De Pediatria. 2021; 97: 116–139.

[35] Siracusa L, Cascio A, Giordano S, Medaglia AA, Restivo GA, Pirrone I, et al. Neurological complications in pediatric patients with SARS-CoV-2 infection: a systematic review of the literature. Italian Journal of Pediatrics. 2021; 47: 123.

[36] Panda PK, Sharawat IK, Panda P, Natarajan V, Bhakat R, Dawman L. Neurological complications of SARS-CoV-2 infection in children: a systematic review and meta-analysis. Journal of Tropical Pediatrics. 2021; 67: fmaa070.

[37] Andina D, Belloni-Fortina A, Bodemer C, Bonifazi E, Chiriac A, Colmenero I, et al. Skin manifestations of COVID-19 in children: part 1. Clinical and Experimental Dermatology. 2021; 46: 444–450.

[38] Andina D, Belloni-Fortina A, Bodemer C, Bonifazi E, Chiriac A, Colmenero I, et al. Skin manifestations of COVID-19 in children: part 2. Clinical and Experimental Dermatology. 2021; 46: 451–461.

[39] Andina D, Belloni-Fortina A, Bodemer C, Bonifazi E, Chiriac A, Colmenero I, et al. Skin manifestations of COVID-19 in children: part 3. Clinical and Experimental Dermatology. 2021; 46: 462–472.

[40] Li H, Zhao Y, Zhou L. Cutaneous manifestations in children with SARS-CoV-2 infection and/or COVID-19: what do we know after 10 months under this pandemic? International Journal of Dermatology. 2022; 61: 39–45.

[41] Henry BM, Benoit SW, de Oliveira MHS, Hsieh WC, Benoit J, Ballout RA, et al. Laboratory abnormalities in children with mild and severe coronavirus disease 2019 (COVID-19): a pooled analysis and review. Clinical Biochemistry. 2020; 81: 1–8.

[42] Jutzeler CR, Bourguignon L, Weis CV, Tong B, Wong C, Rieck B, et al. Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: a systematic review and meta-analysis. Travel Medicine and Infectious Disease. 2020; 37: 101825.

[43] Karbuz A, Akkoc G, Bedir Demirdag T, Yilmaz Ciftdogan D, Ozer A, Cakir D, et al. Epidemiological, clinical, and laboratory features of children with COVID-19 in Turkey. Frontiers in Pediatrics. 2021; 9: 172.

[44] Wang JJ, Hu Z, Chen JY. Characteristics of abnormal serum creatine kinase-MB levels in children with COVID-19. World Journal of Pediatrics volume. 2021; 17: 326–328.

[45] Lu W, Yang L, Li X, Sun M, Zhang A, Qi S, et al. Early immune responses and prognostic factors in children with COVID-19: a single-center retrospective analysis. BMC Pediatrics. 2021; 21: 181.

[46] Costagliola G, Spada E, Consolini R. Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents. Pediatric Rheumatology. 2021; 19: 68.

[47] Chou J, Thomas PG, Randolph AG. Immunology of SARS-CoV-2 infection in children. Nature Immunology. 2022; 23: 177–185.

[48] Hoang A, Chorath K, Moreira A, Evans M, Burmeister-Morton F, Burmeister F, et al. COVID-19 in 7780 pediatric patients: a systematic review. EClinicalMedicine. 2020; 24: 100433.

[49] Saleh M, Alkofide A, Alshammari A, Siddiqui K, Owaidah T. Changes in hematological, clinical and laboratory parameters for children with COVID-19: Single-center experience. Journal of Blood Medicine. 2021; 12: 819–826.

[50] Shahid S, Raza M, Junejo S, Maqsood S. Clinical features and outcome of COVID-19 positive children from a tertiary healthcare hospital in Karachi. Journal of Medical Virology. 2021; 93: 5988–5997.

[51] García-González P, Tempio F, Fuentes C, Merino C, Vargas L, Simon V, et al. Dysregulated immune responses in COVID-19 patients correlating with disease severity and invasive oxygen requirements. Frontiers in Immunology. 2021; 12: 769059.

[52] Hanna SJ, Codd AS, Gea-Mallorqui E, Scourfield DO, Richter FC, Ladell K, et al. T cell phenotypes in COVID-19—a living review. Oxford Open Immunology. 2021; 2: fmaa045.

[53] Vella LA, Giles JR, Baxter AE, Oldridge DA, Diorio C, Kuri-Cervantes L, et al. Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19. Science Immunology. 2021; 6: eabf7570.

[54] Gkantaras A, Taparkou A, Papadimitriou E, Michailidou E, Tsiatsiou O, Milioudi M, et al. Immunophenotyping of peripheral leukocyte subsets in children with acute SARS‐CoV‐2 infection and multisystem inflammatory syndrome reveals distinct patterns of immunological re-sponse. Conference: 6th European Congress of Immunology. Abstracts. Location Virtual. Date September 1‐4, 2021. The European Journal of Immunology. 2021;51(S1):362. P‐0936.

[55] Neeland MR, Bannister S, Clifford V, Nguyen J, Dohle K, Overmars I, et al. Children and adults in a household cohort study have robust longitudinal immune responses following SARS-CoV-2 infection or exposure. Frontiers in Immunology. 2021; 12: 741639.

[56] Tian X, Bai Z, Cao Y, Liu H, Liu D, Liu W, et al. Evaluation of clinical and immune responses in recovered children with mild COVID-19. Viruses. 2022; 14: 85.

[57] Liu Y, Ebinger JE, Mostafa R, Budde P, Gajewski J, Walker B, et al. Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection. Journal of Translational Medicine. 2021; 19: 524.

[58] Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022; 185: 881–895.

[59] Delahoy MJ, Ujamaa D, Whitaker M, O’Halloran A, Anglin O, Burns E, et al. Hospitalizations associated with COVID-19 among children and adolescents—COVID-NET, 14 States, March 1,2020–August 14, 2021. MMWR. Morbidity and Mortality Weekly Report. 2021; 70: 1255–1260.

[60] Marks KJ, Whitaker M, Anglin O, Milucky J, Patel K, Pham H, et al. Hospitalizations of children and adolescents with laboratory-confirmed COVID-19—COVID-NET, 14 States, July 2021–January 2022. MMWR. Morbidity and Mortality Weekly Report. 2022; 71: 271–278.

[61] Ward JL, Harwood R, Smith C, Kenny S, Clark M, Davis PJ, et al. Risk factors for PICU admission and death among children and young people hospitalized with COVID-19 and PIMS-TS in England during the first pandemic year. Nature Medicine. 2022; 28: 193–200.

[62] Nachega JB, Sam-Agudu NA, Machekano RN, Rabie H, Zalm MM van der, Redfern A, et al. Assessment of clinical outcomes among children and adolescents hospitalized with COVID-19 in 6 sub-saharan African countries. JAMA pediatrics. 2022; 176: e216436.

[63] Woodruff RC, Campbell AP, Taylor CA, Chai SJ, Kawasaki B, Meek J, et al. Risk factors for severe COVID-19 in children. Pediatrics. 2022; 149: e2021053418.

[64] Madani S, Shahin S, Yoosefi M, Ahmadi N, Ghasemi E, Koolaji S, et al. Red flags of poor prognosis in pediatric cases of COVID-19: the first 6610 hospitalized children in Iran. BMC Pediatrics. 2021; 21: 563.

[65] Riffe T, Acosta E, Aburto JM, Alburez-Gutierrez D, Basellini U, Altová A, et al. COVerAGE-DB: a database of age-structured COVID-19 cases and deaths. MPIDR Working Paper WP-2020-032. 2020;1–12.

[66] UNICEF Data. Child mortality and COVID-19. 2022. Available at: https://data.unicef.org/topic/child-survival/covid-19/ (Accessed: 13 March 2022).

[67] Smith C, Odd D, Harwood R, Ward J, Linney M, Clark M, et al. Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year. Nature Medicine. 2022; 28: 185–192.

[68] Bundle N, Dave N, Pharris A, Spiteri G, Deogan C, Suk JE. COVID-19 trends and severity among symptomatic children aged 0–17 years in 10 European Union countries, 3 August 2020 to 3 October 2021. Eurosurveillance. 2021; 26: 2101098.

[69] Harwood R, Yan H, Talawila Da Camara N, Smith C, Ward J, Tudur-Smith C, et al. Which children and young people are at higher risk of severe disease and death after hospitalisation with SARS-CoV-2 infection in children and young people: a systematic review and individual patient meta-analysis. EClinicalMedicine. 2022; 44: 101287.

[70] Carias C, Pawaskar M, Nyaku M, Conway JH, Roberts CS, Finelli L, et al. Potential impact of COVID-19 pandemic on vaccination coverage in children: a case study of measles-containing vaccine administration in the United States (US) vaccine. 2021; 39: 1201–1204.

[71] Zhong Y, Clapham HE, Aishworiya R, Chua YX, Mathews J, Ong M, et al. Childhood vaccinations: hidden impact of COVID-19 on children in Singapore. Vaccine. 2021; 39: 780–785.

[72] SeyedAlinaghi S, Karimi A, Mojdeganlou H, Alilou S, Mirghaderi SP, Noori T, et al. Impact of COVID-19 pandemic on routine vaccination coverage of children and adolescents: a systematic review. Health Science Reports. 2022; 5: e00516.

[73] Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. The Lancet. 2020; 395: 1607–1608.

[74] Darby JB, Jackson JM. Kawasaki disease and multisystem inflammatory syndrome in children: an overview and comparison. American Family Physician. 2021; 104: 244–252.

[75] Kiss A, Ryan PM, Mondal T. Management of COVID-19-associated multisystem inflammatory syndrome in children: a comprehensive literature review. Progress in Pediatric Cardiology. 2021; 63: 101381.

[76] Multisystem Inflammatory Syndrome. Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C). 2020. Available at: https://www.cdc.gov/mis/mis-c/hcp/index.html (Accessed: 21 March 2022).

[77] Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American college of rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 1. Arthritis & Rheumatology. 2020; 72: 1791–1805.

[78] World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19: scientific brief. 2020. Avail-able at: https://apps.who.int/iris/handle/10665/332095 (Ac-cessed: 21 March 2022).

[79] Kaushik A, Gupta S, Sood M, Sharma S, Verma S. A systematic review of multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection. The Pediatric Infectious Disease Journal. 2020; 39: e340-e346.

[80] Yasuhara J, Watanabe K, Takagi H, Sumitomo N, Kuno T. COVID-19 and multisystem inflammatory syndrome in children: a systematic review and meta-analysis. Pediatric Pulmonology. 2021; 56: 837-848.

[81] Centers for Disease Control and Prevention. COVID data tracker. 2022. Available at: https://covid.cdc.gov/covid-data-tracker/#datatracker-home (Accessed: 21 March 2022).

[82] McArdle AJ, Vito O, Patel H, Seaby EG, Shah P, Wilson C, et al. Treatment of multisystem inflammatory syndrome in children. The New England Journal of Medicine. 2021; 385: 11–22.

[83] Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al. Multisystem inflammatory syndrome in children in New York state. New England Journal of Medicine. 2020; 383: 347–358.

[84] World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. 2021. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (Accessed: 27 March 2022).

[85] Stephenson T, Allin B, Nugawela MD, Rojas N, Dalrymple E, Pinto Pereira SM, et al. Long COVID (post-COVID-19 condition) in children: a modified Delphi process. Archives of Disease in Childhood.2022; archdischild-2021-323624.

[86] Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, et al. Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain, Behavior, and Immunity. 2022; 101: 93–135.

[87] Stephenson T, Pinto Pereira SM, Shafran R, de Stavola BL, Rojas N, McOwat K, et al. Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study. The Lancet Child & Adolescent Health. 2022; 6: 230–239.

[88] Brackel CLH, Lap CR, Buddingh EP, Houten MA, Sande LJTM, Langereis EJ, et al. Pediatric long-COVID: an overlooked phenomenon?Pediatric Pulmonology. 2021; 56: 2495–2502.

[89] Zimmermann P, Pittet LF, Curtis N. How common is long COVID in children and adolescents? Pediatric Infectious Disease Journal. 2021; 40: e482–e487.

[90] Zimmermann P, Pittet LF, Finn A, Pollard AJ, Curtis N. Should children be vaccinated against COVID-19? Archives of Disease in Childhood. 2022; 107: e1.3–e1e8.

[91] Ledford H. Do vaccines protect against long COVID? what the data say. Nature. 2021; 599: 546–548.

[92] Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID symptom study app: a prospective, community-based, nested, case-control study. The Lancet Infectious Diseases. 2022; 22: 43–55.

[93] Shah SGS, Nogueras D, van Woerden HC, Kiparoglou V. The COVID-19 pandemic: a pandemic of lockdown loneliness and the role of digital technology. Journal of Medical Internet Research. 2020; 22: e22287.

[94] Zhao N, Zhou G. COVID-19 stress and addictive social media use (SMU): mediating role of active use and social media flow. Frontiers in Psychiatry. 2021; 12: 635546.

[95] Daniel SJ. Education and the COVID-19 pandemic. Prospects. 2020; 49: 91–96.

[96] Schneider SL, Council ML. Distance learning in the era of COVID-19. Archives of Dermatological Research. 2021; 313: 389–390.

[97] United Nations Children’s Fund. Beyond Masks: Societal impacts of COVID-19 and accelerated solutions for children and adolescents. 2020. Available at: https://www.unicef-irc.org/publications/1149-beyond-masks-societal-impacts-of-covid-19-and-accelerated-solutions-for-children-and-adolescents.html (Accessed: 28 March 2022).

[98] Shukla V V, Shah RC. Vaccinations in primary care. The Indian Journal of Pediatrics. 2018; 85: 1118–1127.

[99] Golob JL, Lugogo N, Lauring AS, Lok AS. SARS-CoV-2 vaccines: a triumph of science and collaboration. JCI Insight. 2021; 6: e149187.

[100] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine. 2020; 383: 2603–2615.

[101] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine. 2021; 384: 403–416.

[102] Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. 2020; 396: 467–478.

[103] Stephenson KE, Le Gars M, Sadoff J, De Groot AM, Heerwegh D, Truyers C, et al. Immunogenicity of the Ad26.COV2.S vaccine for COVID-19. JAMA. 2021; 325: 1535–1544.

[104] Frenck RW, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New England Journal of Medicine. 2021; 385: 239–250.

[105] Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. New England Journal of Medicine. 2022; 386: 35–46.

[106] Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. New England Journal of Medicine. 2021; 385: 2241–2251.

[107] Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. The Lancet Infectious Diseases. 2022; 22: 196–208.

[108] Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases. 2021; 21: 1645–1653.

[109] Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. The Lancet Infectious Diseases. 2021; 21: 950–961.

[110] Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Frontiers in Immunology. 2019; 10: 594.

[111] Dorabawila V, Hoefer D, Bauer UE, Bassett MT, Lutterloh E, Rosenberg ES. Effectiveness of the BNT162b2 vaccine among children 5–11 and 12–17 years in New York after the emergence of the omicron variant. medRxiv. 2022.

[112] Fowlkes AL, Yoon SK, Lutrick K, Gwynn L, Burns J, Grant L, et al. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5–11 years and adolescents aged 12–15 years—PROTECT cohort, July 2021–February 2022. Morbidity and Mortality Weekly Report. 2022; 71: 422–428.

[113] Klein NP, Stockwell MS, Demarco M, Gaglani M, Kharbanda AB, Irving SA, et al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5–17 years—VISION network, 10 States, April 2021–January 2022. Morbidity and Mortality Weekly Report. 2022; 71: 352–358.

[114] Price AM, Olson SM, Newhams MM, Halasa NB, Boom JA, Sahni LC, et al. BNT162b2 protection against the omicron variant in children and adolescents. The New England Journal of Medicine. 2022; 386: 1899–1909.

[115] Shi DS, Whitaker M, Marks KJ, Anglin O, Milucky J, Patel K, et al. Hospitalizations of children aged 5–11 years with laboratory-confirmed COVID-19—COVID-NET, 14 States, March 2020–February 2022. Morbidity and Mortality Weekly Report. 2022; 71: 574–581.

[116] CDC. COVID-19 vaccines for children and teens. 2022. Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/children-teens.html (Accessed: 21 March 2022).

[117] Canada.ca. Vaccines for children: COVID-19. 2022. Available at: https://www.canada.ca/en/public-health/services/vaccination-children/covid-19.html (Accessed: 21 March 2022).

[118] Australian Government Department of Health. COVID-19 vaccination—resources for parents of children aged 5 to 11. 2022. Available at: https://www.health.gov.au/resources/collections/covid-19-vaccination-resources-for-parents-of-children-aged-5-to-11#fact-sheets (Accessed: 21 March 2022).

[119] Corona Traffic Light Model (Ramzor) Website. COVID-19 vaccine for children. 2022. Available at: https://corona.health.gov.il/en/vaccine-for-covid/under-12/ (Accessed: 21 March 2022).

[120] The Japan Times. COVID-19 vaccinations for young children begin in Japan as omicron continues to spread. 2022. Available at: https://www.japantimes.co.jp/news/2022/02/26/national/children-vaccinations-begin/ (Accessed: 21 March 2022).

[121] Euronews. COVID vaccines: Which countries are vaccinating children over 5 and how do they compare? 2022. Available at: https: //www.euronews.com/next/2022/02/25/covid-vaccine-for-children-who-in-europe-is-leading-the-race (Accessed: 21 March 2022).

[122] The Guardian. Five- to 11-year-old children in England to be offered covid vaccine. 2022. Available at: https://www.theguardian.com/world/2022/feb/16/five--to-11-year-old-children-in-england-to-be-offered-covid-vaccine (Accessed: 21 March 2022).

[123] GOV.UK. JCVI statement on vaccination of children aged 5 to 11 years old. 2021. Available at: https://www.gov.uk/government/publications/jcvi-update-on-advice-for-covid-19-vaccination-of-children-aged-5-to-11/jcvi-statement-on-vaccination-of-children-aged-5-to-11-years-old (Accessed: 21 March 2022).

[124] Reuters. Sweden decides against recommending COVID vaccines for kids aged 5–11. 2022. Available at: https://www.reuters. com/world/europe/sweden-decides-against-recommending-covid-vaccines-kids-aged-5-12-2022-01-27/ (Accessed: 21 March 2022).

[125] Dyer O. Covid-19: US and China prepare for mass vaccination of children under 12. The BMJ. 2021;375:n2631.

[126] The New York Times. In its war on Covid-19, China calls on ‘little inoculated warriors’. Year. Available at: https://www.nytimes.com/ 2021/12/06/business/china-covid-vaccine-children.html (Accessed: 13 March 2022).

[127] Bloomberg. China aims to vaccinate all kids age 3 and over against covid by end of 2021. 2021. Available at: https://www.bloomberg. com/news/articles/2021-11-15/china-aims-to-vaccinate-all-kids-aged-three-and-over-by-year-end (Accessed: 13 March 2022).

[128] Reuters. India vaccinates 3.8 million teens in new COVID-19 inoculation push. 2022. Available at: https://www.reuters.com/business/healthcare-pharmaceuticals/india-launches-drive-vaccinate-children-before-feared-omicron-surge-2022-01-03/ (Accessed: 13 March 2022).

[129] NBC NEWS. In Cuba, most children 2 and up are vaccinated against Covid-19. 2022. Available at: https://www.nbcnews.com/news/latino/cuba-children-2-are-vaccinated-covid-19-rcna18147 (Accessed: 13 March 2022).

[130] El Bcheraoui C, Weishaar H, Pozo-Martin F, Hanefeld J. Assessing COVID-19 through the lens of health systems’ preparedness: time for a change. Global Health. 2020; 16: 1–5.

[131] Laukkanen L, Lahtinen S, Liisanantti J, Kaakinen T, Ehrola A, Raatiniemi L. Early impact of the COVID-19 pandemic and social restrictions on ambulance missions. European Journal of Public Health. 2021; 31: 1090–1095.

[132] Siettos C, Anastassopoulou C, Tsiamis C, Vrioni G, Tsakris A. A bulletin from Greece: a health system under the pressure of the second COVID-19 wave. Pathogens and Global Health. 2021; 115: 133–134.

[133] Trentini F, Marziano V, Guzzetta G, Tirani M, Cereda D, Poletti P, et al. Pressure on the health-care system and intensive care utilization during the COVID-19 outbreak in the lombardy region of Italy: a retrospective observational study in 43,538 hospitalized patients. American Journal of Epidemiology. 2022; 191: 137–146.

[134] Zimmermann P, Curtis N. Why is COVID-19 less severe in children? a review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Archives of Disease in Childhood. 2021; 106: 429–439.

[135] Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine. 2021; 385: 1761–1773.

[136] Laisuan W. COVID-19 vaccine anaphylaxis: current evidence and future approaches. Frontiers in Allergy. 2021; 2: 801322.

[137] Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek

A. Myocarditis and pericarditis after vaccination for COVID-19. JAMA. 2021; 326: 1210.

[138] Larson KF, Ammirati E, Adler ED, Cooper LT, Hong KN, Saponara G, et al. Myocarditis after BNT162b2 and mRNA-1273 vaccination. Circulation. 2021; 144: 506–508.

[139] Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. New England Journal of Medicine. 2021; 385: 2140–2149.

[140] Hause AM, Gee J, Baggs J, Abara WE, Marquez P, Thompson D, et al. COVID-19 vaccine safety in adolescents aged 12–17 years—United States, December 14, 2020–July 16, 2021. Morbidity and Mortality Weekly Report. 2021; 70: 1053–1058.

[141] Boehmer TK, Kompaniyets L, Lavery AM, Hsu J, Ko JY, Yusuf H, et al. Association between COVID-19 and myocarditis using hospital-based administrative data—United States, March 2020–January 2021. Morbidity and Mortality Weekly Report. 2021; 70: 1228–1232.

[142] Gellad WF. Myocarditis after vaccination against covid-19. The BMJ. 2021; 375: n3090.

[143] European Medicines Agency. Pharmacovigilance plan of the EU regulatory network for COVID-19 vaccines. 2020. Available at: https://www.ema.europa.eu/en/documents/other/pharmacovigilance-plan-eu-regulatory-network-covid-19- vaccines_en.pdf (Accessed: 29 March 2022).

[144] World Health Organization. Pharmacovigilance of COVID-19 vaccines. 2021. Available at: https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/covid-19-vaccines/pharmacovigilance (Accessed: 29 March 2022).

[145] European Medicines Agency. COVID-19 vaccines: development, evaluation, approval and monitoring. 2020. Available at: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-development-evaluation-approval-monitoring (Accessed: 29 March 2022).

[146] Wilkinson D, Finlay I, Pollard AJ, Forsberg L, Skelton A. Should we delay covid-19 vaccination in children? The BMJ. 2021;374: n1687.

[147] Eberhardt CS, Siegrist C. Is there a role for childhood vaccination against COVID-19? Pediatric Allergy and Immunology. 2021; 32: 9–16.

[148] Pan F, Zhao H, Nicholas S, Maitland E, Liu R, Hou Q. Parents’ decisions to vaccinate children against COVID-19: a scoping review. Vaccines. 2021;9: 1476.

[149] Islam MS, Kamal AHM, Kabir A, Southern DL, Khan SH, Murshid Hasan SM, et al. COVID-19 vaccine rumors and conspiracy theories: the need for cognitive inoculation against misinformation to improve vaccine adherence. PLoS One. 2021;16: e0251605.

[150] Klass P, Ratner AJ. Vaccinating children against Covid-19—the lessons of measles. New England Journal of Medicine. 2021; 384: 589–591.

[151] She J, Liu L, Liu W. Providing children with COVID-19 vaccinations is challenging due to lack of data and wide-ranging parental acceptance. Acta Paediatrica. 2022; 111: 35–44.

[152] Campagnani G, Bardanzellu F, Pintus MC, Fanos V, Marcialis MA. COVID-19 vaccination in children: an open question. Current Pediatric Reviews. 2022; 18: 226–226.

[153] Opel DJ, Diekema DS, Ross LF. Should we mandate a COVID-19 vaccine for children? JAMA Pediatrics. 2021; 175: 125.

[154] Buchy P, Buisson Y, Cintra O, Dwyer DE, Nissen M, Ortiz de Lejarazu R, et al. COVID-19 pandemic: lessons learned from more than a century of pandemics and current vaccine development for pandemic control. International Journal of Infectious Diseases. 2021; 112: 300–317.

[155] The New York Times. How long will a vaccine really take? 2020. Available at: https://www.nytimes.com/interactive/2020/04/ 30/opinion/coronavirus-covid-vaccine.html (Accessed: 29 March 2022).

[156] European Commission. Vaccines. 2021. Available at: https://ec.europa.eu/info/research-and-innovation/research-area/health-research-and-innovation/coronavirus-research-and-innovation/vaccines_en (Accessed: 29 March 2022).

[157] Pottegård A, Kurz X, Moore N, Christiansen CF, Klungel O. Con-siderations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic. Pharmacoepidemiology & Drug Safrty. 2020;29:825–831.

[158] Marinus R, Mofid S, Mpandzou M, Kühler TC. Rolling reviews during COVID-19: the European Union experience in a global context. Clinical Therapeutics. 2022; 44: 352–363.

[159] European Medicines Agency. Conditional marketing authorisation. 2022. Available at: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/conditional-marketing-authorisation (Accessed: 29 March 2022).

[160] Jetelina K. Vaccine for 5-11 year olds: ACIP cliff notes. 2021. Avail-able at: https://yourlocalepidemiologist.substack.com/p/vaccine-for-5-11-year-olds-acip-cliff?s=r (Accessed: 30 March 2022).

[161] Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwels KB, et al. Effect of Covid-19 vaccination on transmission of alpha and delta variants. The New England Journal of Medicine. 2022;386:744–756.

[162] WHO. COVAX: working for global equitable access to COVID-19 vaccines. 2022. Available at: https://www.who.int/initiatives/act-accelerator/covax (Accessed: 30 March 2022).